Flecainide can be useful in long QT syndrome type 3, an arrhythmogenic cardiomyopathy caused by gain-of-function mutations in the SCN5A-encoded Nav1.5 sodium channel involving a pathological increase in late sodium current and, consequently, prolonging QTc [27,28,29]. Here, SCN5A is linked to long QT syndrome 3.